Financing ·
Subsequent to the March 31, 2026, 10-Q filing, warrants to purchase 1,361,500 shares of common stock were exercised…
MBRXMoleculin Biotech, Inc.
Subsequent to the March 31, 2026, 10-Q filing, warrants to purchase 1,361,500 shares of common stock were exercised, generating gross proceeds of approximately $2.7 million. As of June 29, 2026, the company had 7,065,000 shares of common stock outstanding. Moleculin Biotech, Inc. is a biotechnology company focused on developing clinical-stage drug candidates.